- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Cesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina Lineberger Advanced Cellular Therapeutics Facility for X-Series
Cesca Therapeutics (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that it has entered into an evaluation agreement with the University of North Carolina Lineberger Advanced Cellular Therapeutics Facility (ACT) to assess Cesca’s patented and proprietary X-Series products for automated, closed system cellular processing. As quoted in the …
Cesca Therapeutics (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that it has entered into an evaluation agreement with the University of North Carolina Lineberger Advanced Cellular Therapeutics Facility (ACT) to assess Cesca’s patented and proprietary X-Series products for automated, closed system cellular processing.
As quoted in the press release:
X-Series products are part of Cesca’s CAR-TXpress™ platform, which is an automated system that selects target cells using its patented, buoyancy-activated cell separation (X-BACS™) technology. The system is a multi-device platform designed to automate many of the manual steps currently involved in cell processing. As such, the CAR-TXpress system can provide a comprehensive and commercially viable, automated cellular manufacturing and control (CMC) solution for the development of CAR-T as well as CAR-NK therapeutics.
“As a pioneer in the research and development of novel CAR-T based therapeutics, we are delighted that ACT has selected our X-Series products for this important evaluation,” said Phil Coelho, chief technology officer of ThermoGenesis, Cesca’s device subsidiary. “The complexity of the CAR-T manufacturing process stands as a significant obstacle to the more rapid uptake of these ground-breaking therapies, contributing to lengthy treatment times and high costs. We believe CAR-TXpress can automate key steps in the process while at the same time improving cell yields and consistency. We are hopeful that this evaluation will lead to a long and productive collaboration with ACT.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â